JPH02142734A - Method for treating dermatosis using propolis together - Google Patents
Method for treating dermatosis using propolis togetherInfo
- Publication number
- JPH02142734A JPH02142734A JP63297931A JP29793188A JPH02142734A JP H02142734 A JPH02142734 A JP H02142734A JP 63297931 A JP63297931 A JP 63297931A JP 29793188 A JP29793188 A JP 29793188A JP H02142734 A JPH02142734 A JP H02142734A
- Authority
- JP
- Japan
- Prior art keywords
- ointment
- propolis
- atopic dermatitis
- manufactured
- rinderon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000017520 skin disease Diseases 0.000 title claims abstract description 10
- 241000241413 Propolis Species 0.000 title claims abstract description 9
- 229940069949 propolis Drugs 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 8
- 206010048768 Dermatosis Diseases 0.000 title abstract 3
- 239000002674 ointment Substances 0.000 claims abstract description 22
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 9
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims abstract description 7
- 230000003115 biocidal effect Effects 0.000 claims abstract description 7
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 claims abstract description 6
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims abstract 2
- 239000002075 main ingredient Substances 0.000 claims description 12
- 229960004311 betamethasone valerate Drugs 0.000 claims description 6
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 6
- 229950010121 ufenamate Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 2
- 229940070710 valerate Drugs 0.000 abstract description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229960002537 betamethasone Drugs 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 206010033733 Papule Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- -1 butyl flufenamic acid Chemical compound 0.000 description 2
- 229960004369 flufenamic acid Drugs 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、フルフェナム酸ブチルを主成分とするところ
のコンベック軟膏及び吉草酸ベタメタゾン・抗生物質の
硫酸ゲンタマイシンを主成分とするリンゾロンＶＧ軟膏
による主しとしてアトピー性皮膚炎等の皮膚病治療方法
に間するものである。Detailed Description of the Invention [Industrial Field of Application] The present invention is based on Convec ointment, which contains butyl flufenamic acid as a main ingredient, and Rinzolon VG ointment, which contains betamethasone valerate and the antibiotic gentamicin sulfate as main ingredients. It is used as a method for treating skin diseases such as atopic dermatitis.
［従来の技術］
従来アトピー性皮膚炎等の皮膚病を治療する方法として
、フルフェナム酸ブチルを主成分とするところのコンベ
ック軟膏（商標名、東京田辺製薬製）及び吉草酸ベタメ
タゾン・抗生物質の硫酸ゲンタマイシンを主成分とする
ところのリンゾロンＶＧ軟膏（商標名、ジオツギ製薬製
）を併せて患部に塗布もしくは貼布することよりなるも
のがある。[Prior art] Conventionally, as a method of treating skin diseases such as atopic dermatitis, Convec ointment (trade name, manufactured by Tokyo Tanabe Pharmaceutical Co., Ltd.) containing butyl flufenamic acid as the main ingredient and betamethasone valerate/antibiotic sulfuric acid have been used. There is also a method that consists of applying or pasting Rinzolon VG ointment (trade name, manufactured by Geotsugi Pharmaceutical Co., Ltd.), which contains gentamicin as the main ingredient, to the affected area.
上記薬剤の効能・効果は、コンベック軟膏の主成分であ
るフルフェナム酸ブチルの抗炎症作用ならびに沈痛作用
・リンゾロンＶＧ軟膏を構成するそれぞれ吉草酸ベタメ
タシンの局所抗炎症作用及び硫酸ゲンタマイシンの抗菌
作用によるものである。The efficacy and effects of the above drugs are due to the anti-inflammatory and analgesic effects of butyl flufenamate, the main ingredient of Convec ointment, and the local anti-inflammatory effects of betamethacin valerate and the antibacterial effects of gentamicin sulfate, which make up Rinzolon VG ointment. be.
［発明が解決しようとする課題］
上記、従来のコンベック軟膏及びリンゾロンＶＧ軟膏併
用によるアトピー性皮膚炎治療方法はかなり有効な治療
方法であるが、副作用があり、長期連用を避ける必要が
あり、まだ必ずしも満足すべき効能・効果を発揮するま
でに至っていないと言う問題点があり、その改善が求め
られていた。[Problems to be solved by the invention] The above-mentioned conventional method for treating atopic dermatitis using a combination of Convec ointment and Rinzolon VG ointment is a fairly effective treatment method, but it has side effects and long-term use must be avoided. There is a problem in that they do not necessarily exhibit satisfactory efficacy and effects, and improvements have been sought.
本発明は、上記課題を解決したプロポリス併用によるア
トピー性皮膚炎等の皮膚病治療方法を提供することを目
的としている。An object of the present invention is to provide a method for treating skin diseases such as atopic dermatitis using propolis in combination, which solves the above problems.
［！！！題を解決するための手段１
以上の課題を解決した本発明に係わるアトピー性皮膚炎
等の皮膚病治療方法はフルフェナム酸ブチルを主成分と
するところのコンベック軟膏及び吉草酸ベタメタゾン・
抗生物質の硫酸ゲンタマイシンを主成分とするところの
リンゾロンＶＧ軟膏に、蜜蜂の巣より抽出したところの
プロポリスを加えて、塗布もしくは貼布することよりな
るものである。[! ! ! Means for Solving the Problem 1 The method for treating skin diseases such as atopic dermatitis according to the present invention, which solves the above problems, uses Convec ointment containing butyl flufenamate as a main ingredient and betamethasone valerate.
It consists of adding propolis extracted from honeycomb to Linzolon VG ointment, which has the antibiotic gentamicin sulfate as its main ingredient, and applying or pasting the mixture.
［作用］
本発明は、上記のように構成されるため、プロポリスが
フルフェナム酸ブチルを主成分とするところのコンベッ
ク軟膏及び吉草酸ベタメタゾン・抗生物質の硫酸ゲンタ
マイシンを主成分とするリンゾロンＶＧ軟膏の治療効果
を促進し、従来のものに比しアトピー性皮膚炎等の皮膚
病の症状を和らげ、その治癒を早める効果がある。[Function] The present invention is configured as described above, and thus can be used for treatment with Convec ointment in which propolis contains butyl flufenamate as the main ingredient, and Rinzolon VG ointment in which the main ingredient is betamethasone valerate and the antibiotic gentamicin sulfate. It has the effect of alleviating the symptoms of skin diseases such as atopic dermatitis and hastening their healing compared to conventional products.
［実施例］
実施例について説明すると、従来の治療方法によっては
効果が挙がらなかったひじ等に生していた赤丘疹に対し
て、フルフェナム酸ブチルを主成分とするところのコン
ベック軟膏（商標名、東京田辺製薬製）１０ｇ、及び吉
草酸ベタメタゾン・抗生物質の硫酸ゲンタマイシンを主
成分とするところのリンゾロンＶＧ軟膏（商標名、ジオ
ツギ製薬製）０．７ｇ、プロポリス１０滴を併用して治
療を行ったところ、約−週間で赤丘疹が消失した。[Example] To explain an example, Convec ointment (trade name: The treatment was carried out using a combination of 10 g of Rinzolon VG ointment (trade name, manufactured by Geotsugi Pharmaceutical), whose main ingredients are betamethasone valerate and the antibiotic gentamicin sulfate (manufactured by Tokyo Tanabe Pharmaceutical), and 10 drops of propolis. However, the red papules disappeared in about a week.
また、背中−面に生じていた丘疹も、−ケ月連続して治
療を行ったところ、完全に消失した。In addition, the papules that had appeared on the patient's back completely disappeared after several months of continuous treatment.
なお、リンゾロンＶＧはホルモン剤であり、小量を使用
しているとは言え、プロポリスの効力をマイナスにする
可能性がある。したがって丘疹が消失した時点でリンゾ
ロンＶＧに代わり脂溶性のザーネ類を使用することが望
ましい。It should be noted that Rinsolone VG is a hormonal agent, and although it is used in small amounts, it may negatively affect the effectiveness of propolis. Therefore, once the papules have disappeared, it is desirable to use a fat-soluble Zahne instead of Rinzolon VG.
［発明の効果］
本発明は、以上説明したように構成されているため、ア
トピー性皮膚炎等の皮膚病に著効があり、しかも副作用
が少ない。[Effects of the Invention] Since the present invention is configured as described above, it is highly effective against skin diseases such as atopic dermatitis, and has few side effects.
Claims (1)
ベック軟膏と 吉草酸ベタメタゾン・抗生物質の硫酸ゲン タマイシンを主成分とするところのリンデロンＶＧ軟膏 に蜜蜂の巣より抽出したところのプロポリスを加えて、
塗布もしくは貼布することよりなるアトピー性皮膚炎等
の皮膚病治療方法。[Claims] 1. Propolis extracted from honeycomb is added to Convec ointment, which contains butyl flufenamate as the main ingredient, and Rinderon VG ointment, which contains betamethasone valerate and the antibiotic gentamicin sulfate as main ingredients. In addition,
A method for treating skin diseases such as atopic dermatitis, which comprises application or patching.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63297931A JPH02142734A (en) | 1988-11-24 | 1988-11-24 | Method for treating dermatosis using propolis together |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63297931A JPH02142734A (en) | 1988-11-24 | 1988-11-24 | Method for treating dermatosis using propolis together |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02142734A true JPH02142734A (en) | 1990-05-31 |
Family
ID=17852944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63297931A Pending JPH02142734A (en) | 1988-11-24 | 1988-11-24 | Method for treating dermatosis using propolis together |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02142734A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100311761B1 (en) * | 1997-08-25 | 2001-12-28 | 박준태 | Method for producing healthy drug using aloe and garlic |
| WO2002076411A2 (en) * | 2001-03-27 | 2002-10-03 | Dorian Owoc | Dermatological agent for the treatment of skin trauma, especially in burn conditions |
-
1988
- 1988-11-24 JP JP63297931A patent/JPH02142734A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100311761B1 (en) * | 1997-08-25 | 2001-12-28 | 박준태 | Method for producing healthy drug using aloe and garlic |
| WO2002076411A2 (en) * | 2001-03-27 | 2002-10-03 | Dorian Owoc | Dermatological agent for the treatment of skin trauma, especially in burn conditions |
| WO2002076411A3 (en) * | 2001-03-27 | 2003-03-20 | Dorian Owoc | Dermatological agent for the treatment of skin trauma, especially in burn conditions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4210633A (en) | Flurandrenolide film formulation | |
| KR101822589B1 (en) | Use of an oleogel containing triterpene for healing wounds | |
| US20070202155A1 (en) | Low dose no donor-containing transdermal patch | |
| NO985938L (en) | Apparatus for topical treatment of acne and method of preparation thereof | |
| JP2002509867A (en) | Acidified composition for topical treatment of nails and skin | |
| US4012508A (en) | Topical composition and method | |
| US8846646B2 (en) | Topical treatment of skin infection | |
| US4735802A (en) | Topical dermatological composition and method of treatment | |
| DE69825279T2 (en) | USE OF GLUCOSAMINE AND GLUCOSAMINE DERIVATIVES FOR THE FAST RELIEF OF JUCKREIZ OR LOCALIZED PAIN | |
| JPH02142734A (en) | Method for treating dermatosis using propolis together | |
| US4740372A (en) | Composition for treating psoriasis vulgaris and a method for its preparation | |
| RU2233151C2 (en) | Application of tosylchloroamides for treatment of skin and mucosa disease | |
| US5993841A (en) | Pharmaceutical composition and methods for using it | |
| US8741353B1 (en) | Ointment for healing burns and wounds | |
| US5753247A (en) | Method of treating fungal infections | |
| WO2003097070A1 (en) | The pharmaceutical composition comprising a corticosteroid and an antiseptic | |
| RU2085194C1 (en) | Agent for local application | |
| HU198841B (en) | Process for producing composition suitable for treating psoriasis | |
| JPS62155214A (en) | Antiinflammatory drug and method | |
| RU2160092C2 (en) | Antimicrobial preparation for treatment of infected wounds | |
| RU2417086C1 (en) | Agent for treating local allergic exudative-inflammatory and infiltrative-inflammatory skin processes | |
| CZ303849B6 (en) | Medicament for local treatment of burns | |
| RU2682454C1 (en) | Ointment for treatment of thermal burns and method for treatment thereof | |
| JPH01294635A (en) | Pharmaceutical composition for local administration | |
| RU2749369C2 (en) | Method for treating extensive superficial skin lesions |